Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Liquidia and Pharmosa announced they have amended the current exclusive licensing agreement for the development and commercialization of L606.
-
Liquidia will present a poster and host a medical theater at the CHEST 2024 annual meeting hosted by the American College of Chest Physicians this October.
-
MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare...
-
Liquidia Corporation announces raise of $67.5M.
-
Liquidia Corporation (LQDA) announced today that the company will present at two investor conferences this September.
-
Liquidia has filed litigation that challenges the recent decision by the FDA to grant 3-year new clinical investigation exclusivity to Tyvaso DPI.
-
The FDA has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with PAH and PH-ILD.
-
Liquidia Corporation (NASDAQ: LQDA) will present nine encore thematic posters at the 2024 Pulmonary Hypertension Association (PHA) International Conference
-
Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the second quarter ended June 30, 2024.
-
Liquidia Corporation to report second quarter 2024 financial results on August 7, 2024.